Overview
- At the American Society of Clinical Oncology meeting in early June 2026, Penn Medicine and other groups reported that people taking GLP‑1 drugs had about 30% lower odds of being diagnosed with breast cancer compared with nonusers.
- Separate ASCO and journal analyses linked GLP‑1 use to reduced disease progression across tumor types and modest survival gains, including lower colorectal cancer deaths and fewer metastases in endometrial cancer patients.
- A May 11 JAMA Network Open paper and other retrospective studies found lower all‑cause mortality and recurrence in breast cancer patients with obesity or type 2 diabetes who used GLP‑1s over long follow‑up periods.
- Investigators stress that all current findings are observational, note limits such as incomplete data on specific drug, dose and treatment duration, and say these results do not prove causation.
- If randomized trials confirm benefit, clinicians could consider new prevention or treatment uses for GLP‑1s, which would raise questions about who should get them, long‑term safety, cost and equitable access.